Health News Releases

  • Today September 22
September 21, 15:19
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland‘s leading blue chip equity benchmark comprising 20 o
September 18, 17:47
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to s
September 18, 16:00
Medisca Launches Global Peptide Division
Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and
September 18, 15:20
AMRA Medical Earns TIME’s Highest “Outstanding” Rating in World’s Top HealthTech Companies 2026
The 2026 result builds on AMRA’s inclusion in the inaugural ranking in 2025, when the company received a “Very High” designation. Its advancement to the top category reflects continued progress in sci
September 17, 15:15
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth
Rubedo Life Sciences, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.rubedolife.com%2F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2Z
September 17, 10:28
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.[1] The study met its
September 16, 16:35
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsiv
September 16, 08:37
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth
Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished internation
September 15, 10:15
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood a
September 15, 09:50
Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize
From more than 134,000 registrations spanning 214 countries and economies, Nurse Agimol Pradeep from United Kingdom has been announced as the winner of the Aster Guardians Global Nursing Award 2026. A
September 14, 17:23
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54602408&newsitemid=20260914748441&lan=en-US&anchor=TSE%3A4
September 11, 13:30
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Chugai Pharmaceutical Co., Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.chugai-pharm.co.jp%2Fenglish%2Findex.html&esheet=54600887&newsitemid=20260909923883&lan=en-US&anc
September 10, 15:25
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nejm.org%2Fstoken%2Fdefault%2Bdomain%2FREPRINTS_375
September 10, 09:23
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 (“H1 2026”). P
September 04, 11:40
Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. F
September 03, 17:50
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd.
September 02, 11:45
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines (https://beonemedicines.com/), Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access
September 02, 11:00
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedul
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com (https://www.angelaligner.com/)), the second largest clear aligner supplier by revenue, announced today that its reven
September 02, 10:30
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse
September 02, 10:00
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) o
September 01, 10:40
Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis
QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectr
MIMRYLO Logo
August 30, 14:12
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54593875&newsitemid=20260824773270&lan=en-US&anchor=TSE%3A4
August 27, 15:50
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles
NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its “Ultra-thin and narrow-width sta
August 27, 09:35
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54594386&newsitemid=20260825943679&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
블라블라
August 24, 16:00
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54590997&newsitemid=20260818063761&lan=en-US&anc
August 24, 11:00
Novotech Strengthens Presence in Japan with Opening of Tokyo Office
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment bui
August 19, 17:40
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54590849&newsitemid=20260818126011&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 12, 14:01
Align Technology Prevails in China Patent Infringement Action Against Angelalign
Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan
August 11, 10:50
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54586664&newsitemid=20260810801799&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5=
August 10, 10:50
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Co
Eight Ophthalmologists at BGN Eye Clinic Jamsil Specializing in SMILE LASIK, LASEK, ICL, Presbyopia
August 10, 08:00
Is a Lower SMILE LASIK Price Really the Best Choice? Three Things to Consider Beyond Cost
Dr. Se-Kwang Park, Chief Ophthalmologist at BGN Eye Clinic Jamsil, has advised patients on what to consider when selecting a clinic for SMILE LASIK surgery. For many people considering vision corre
August 07, 11:20
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54583421&newsitemid=20260805570642&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
August 06, 10:43
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/stock-information/)) announced that the U.S. Food and Drug Administration (FDA) approved (https://www.fda.gov/news-events/press-announcement
August 05, 14:30
WHOOP Expands Commitment to Women’s Health by Including One-Year Subscription of Natural Cycles° App in Membership
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F%3Fsrsltid%3DAfmBOoqrUNUmqB7UR9PSkcUqTlIlQZFv-cFnFEHe-4KarW-TDybGdsAu&esheet=54582456&newsitemid=20260804399367
August 05, 11:50
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available
August 04, 09:50
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2026-Enterprise-Press-Release-0826&utm_medium=pressrelease&utm_source=prnews&utm_content=First-Plus-SSNC) (Nasdaq: SSNC) toda
July 31, 13:40
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for
July 30, 15:52
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54578194&newsitemid=20260727883646&lan=en-US&anc
July 30, 15:40
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled
July 30, 15:30
Copeland Enters into Exclusive Negotiations to Acquire Dickson, Advancing Cold Chain Leadership
Copeland, a global leader in compression technologies and controls solutions, today announced its entry into exclusive negotiations towards the purchase of Dickson, a portfolio company of May River Ca
July 30, 11:50
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network
Parse Biosciences (https://www.parsebiosciences.com/), the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics (https://xpres
July 24, 16:41
Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the second quarter and first half
July 24, 11:15
Kirin and Blackmores Team Up to Release Cognitive Function Support Supplements in Australia and New Zealand Formulated with Kirin Group’s Cognizin® Citicoline
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Blackmores Limited (Blackmores), Kirin’s group company and Australia’s leading natural health company, are proud to announce the launch
July 23, 15:31
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. · Net sales reached 3.134 billion USD, surpassing 3 billi
July 22, 11:30
Zayed Sustainability Prize’s Beyond2020 Initiative Strengthens Healthcare Resilience for Over 200,000 People in India
Beyond2020, the flagship initiative launched by the Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the deployment of solar-powere
July 21, 14:20
Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension
Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution acr
July 21, 13:30
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong
HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city’s position as a leading hub for physician education, clinical collaboration, and
July 21, 09:25
Clinigen Appoints Greg Skalicky as Chief Executive Officer
Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer
July 20, 15:30
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin - its premium regenerative skincare brand - across the JPAC region. The brand recently launched i
July 19, 13:51
Aqemia and Sanofi Expand Their Research Collaboration
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the
25 per page50 per page75 per page100 per page